CSPC says FDA clears CRB-701 pivotal trial in second-line oropharyngeal cancer
WuXi Biologics added to FTSE4Good Index Series for sixth straight year
WuXi Biologics Recognized by FTSE4Good for the Sixth Consecutive Year, Underscoring Value Creation Through Green CRDMO
Morgan Stanley Remains a Buy on CSPC Pharmaceutical Group (CHJTF)
Akeso doses first patient in Phase Ib/II NSCLC trial of HER3 ADC AK138D1 with ivonescimab
CSPC PHARMA HA1406 Enteric-coated Tablets for Depression Treatment Meet Primary Endpoint in Phase III Clinical Trial